-
1 Comment
Takara Bio Inc is currently in a long term downtrend where the price is trading 1.4% below its 200 day moving average.
From a valuation standpoint, the stock is 87.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.9.
Takara Bio Inc's total revenue rose by 49.9% to $12B since the same quarter in the previous year.
Its net income has increased by 445.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 280.3% to $1B since the same quarter in the previous year.
Based on the above factors, Takara Bio Inc gets an overall score of 4/5.
| CurrencyCode | JPY |
|---|---|
| Exchange | TSE |
| ISIN | JP3460200003 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 107B |
|---|---|
| PE Ratio | 102.07 |
| Target Price | 1170 |
| Dividend Yield | 1.9% |
| Beta | 0.33 |
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV", a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4974.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
